Eye - diabetic macular oedema

The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).

Patient eligibility

The PBS subsidises treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with DMO. This is under Section 85 of the National Health Act 1953.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant and ranibizumab.

Treatment specifics

To be eligible for PBS subsidised treatment with these medications, patients must be treated by:

  • an ophthalmologist
  • an accredited ophthalmology registrar in consultation with an ophthalmologist.

Authority applications

Applying for initial treatment

Apply for authority approval to prescribe initial PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab in writing and either:

All applications must include the completed:

Applications to move between different drugs to treat DMO will require a new initial authority application to be completed.

Applying for continuing treatment

Applications for continuing authority applications to prescribe PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 October 2020